From pro­tein degra­da­tion to 'toad ven­om': An­oth­er five biotechs will make the Nas­daq shuf­fle af­ter fil­ing SEC pa­per­work

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Fri­day proved to be an­oth­er busy day for biotech IPOs, with five more com­pa­nies fil­ing their S-1s and F-1s with the SEC ahead of ex­pect­ed jumps to Nas­daq.

Four biotechs pen­ciled in ini­tial es­ti­mates of $100 mil­lion rais­es: pro­tein-degra­da­tion play­er Monte Rosa, gene edit­ing biotech Graphite Bio, “toad ven­om”-fo­cused GH Re­search and mon­o­clon­al an­ti­body de­vel­op­er El­e­va­tion On­col­o­gy. The fifth com­pa­ny, reagents provider Al­pha Tekno­va, es­ti­mates at least $75 mil­lion with their raise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.